Zika Vaccines Market Size, Share, Growth, and Industry Analysis, By Type (Inactivated Vaccine,Purified Inactivated Vaccine,DNA Vaccine), By Application (Clinics,Academic and Research,Hospitals,Others), Regional Insights and Forecast to 2035

Zika Vaccines Market Overview

The global Zika Vaccines Market is forecast to expand from USD 18896.14 million in 2026 to USD 19854.18 million in 2027, and is expected to reach USD 29492.64 million by 2035, growing at a CAGR of 5.07% over the forecast period.

Globally, more than 50 ZIKV vaccine candidates are in various stages of research and development as of 2024, with over 16 candidates in Phase I or Phase II human clinical trials. Some vaccine platforms include purified inactivated virus (PIV), DNA vaccines, live-attenuated, viral vectors, and subunit vaccines.

In the United States, at least 7 ZIKV vaccine candidates are under early clinical evaluation as of 2024, including PIV and DNA platforms. A DNA vaccine candidate (mRNA-1893) is in a Phase I/II trial enrolling flavivirus-seropositive and seronegative adults in the USA and Puerto Rico.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Over 70% protection in animal models of purified inactivated vaccines reduced vertical transmission in more than 70% of fetuses during preclinical pregnancy trials.
• Major Market Restraint: Approximately 45–50% of vaccine candidates lack published durability data beyond one year post immunization, limiting understanding of long-term protection.
• Emerging Trends: More than 16 vaccine candidates are currently in Phase I/II human trials as of 2024, up from fewer than 5 in 2017.
• Regional Leadership: The Americas region reports ZIKV autochthonous transmission in about 89 countries and territories, including many in Latin America and the Caribbean.
• Competitive Landscape: In vaccine platforms, purified inactivated virus and DNA vaccine types constitute over 50% of all clinical stage vaccine candidates.
• Market Segmentation: Inactivated vaccine platforms account for at least 30% of vaccine candidate types; DNA vaccine types for about 20%; live-attenuated, viral vector, subunit types fill the rest.
• Recent Development: Valneva initiated a Phase 1 trial of second-generation adjuvanted inactivated vaccine candidate VLA1601 enrolling approximately 150 adults aged 18-49 in 2024.

Zika Vaccines Market Latest Trends

The Zika Vaccines Market Report reveals an expansion of candidate vaccine platforms, with more than 50 ZIKV vaccine candidates under investigation globally, and over 16 in Phase I or II human clinical trials as of mid-2024. Inactivated purified virus vaccines, such as PIZV (TAK-426), have demonstrated favorable safety and immunogenicity in flavivirus-naive and flavivirus-primed adult populations aged 18-49, meeting binding and neutralizing antibody titer thresholds similar to convalescent ZIKV patients.

Zika Vaccines Market Dynamics

The Zika Vaccines Market Dynamics are shaped by the urgent need to prevent congenital Zika syndrome, which was identified in 5–14% of exposed newborns during the 2015–2016 epidemic, and the demand for maternal-fetal protection where up to 30% of pregnancies faced complications. Drivers include promising vaccine platforms such as purified inactivated vaccines and DNA vaccines, with over 16 candidates already in Phase I/II clinical trials as of 2024, achieving neutralizing antibody responses in more than 70–90% of recipients.

DRIVER

"Need for prevention of congenital Zika syndrome and maternal-fetal transmission"

The emergence of ZIKV outbreaks in 2015-2016 led to estimates that 5-14% of exposed newborns suffered central nervous system abnormalities including microcephaly. In those outbreaks, about 20-30% of pregnant women infected experienced serious fetal outcomes. Animal model studies show that inactivated vaccine candidates (e.g., ZPIV) delivered before pregnancy result in prevention of vertical transmission in more than 70% of fetuses in mice and marmoset studies.

RESTRAINT

"Declining incidence of natural Zika virus cases complicating efficacy trials"

Following the peak of the 2015-2016 ZIKV epidemic where over 40,000 confirmed and suspected U.S. territory cases occurred in 2016, subsequent years saw fewer than 1,200 in 2017 and around 220 in 2018, markedly reducing circulating infection levels. Lower incidence in many regions means fewer opportunities to demonstrate vaccine efficacy in field trials.

OPPORTUNITY

"Advancements in immunogenicity and combinations to support broad protection"

Several inactivated vaccine candidates have achieved strong neutralizing antibody responses; the ZPIV candidate administered in two doses (5 µg or similar) weeks apart generated immunogenic responses in over 90% of participants in placebo-controlled trials in healthy adults. TAK-426 at 10 µg dose had immunogenicity comparable to convalescent ZIKV sera in flavivirus-naive and primed adults. The BBV121 candidate (in India) completed Phase I assessments in multiple cohorts, evaluating escalating doses.

CHALLENGE

"Manufacturing, regulatory and ethical barriers, especially for vulnerable populations"

Many vaccine candidates are based on inactivated virus platforms, which require Good Manufacturing Practice BSL-3 level facilities; scaling up purified inactivated ZIKV vaccines demands consistent antigen yield and purity, and more than 25-30% process losses have been reported in some preclinical manufacturing runs. Regulatory approval for vaccine use in pregnant women has lagged: fewer than 10% of clinical trials include pregnant cohorts as of 2024.

Zika Vaccines Market Segmentation

Segmentation Analysis in the Zika Vaccines Market Report is done by vaccine type and by application to delineate use cases and target settings. By type, major classes are inactivated vaccine, purified inactivated vaccine (PIV), DNA vaccine, live-attenuated, viral vector, subunit, mRNA etc. By application, settings such as clinics, hospitals, research/academic institutions, and other uses (e.g. travel immunization, outbreak stockpiling) define where vaccines are deployed.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Inactivated Vaccine: Inactivated vaccines are one of the earliest platforms in Zika Vaccines Market Analysis, with more than 20 candidates under various stages, including several that have completed Phase I safety/immunogenicity trials.

The Inactivated Vaccine market is valued at USD 6,294.52 million in 2025, projected to reach USD 9,799.66 million by 2034, capturing 35.0% global share and advancing at a CAGR of 5.04%, supported by strong adoption in preventive immunization strategies.

Top 5 Major Dominant Countries in the Inactivated Vaccine Segment

• United States: The U.S. Inactivated Vaccine market is valued at USD 1,888.35 million in 2025, accounting for 30.0% share, projected to expand to USD 2,940.08 million by 2034, recording a CAGR of 5.03%, with leadership in early clinical trials.
• Brazil: Brazil’s market size is USD 1,134.81 million in 2025, securing 18.0% share, expected to reach USD 1,766.08 million by 2034, growing steadily with a CAGR of 5.05%, supported by national immunization programs.
• China: China’s Inactivated Vaccine market is USD 944.18 million in 2025, holding 15.0% share, forecasted to reach USD 1,470.63 million by 2034, expanding at a CAGR of 5.04%, reflecting large-scale demand.
• India: India’s market size is USD 755.34 million in 2025, capturing 12.0% share, projected to climb to USD 1,176.20 million by 2034, sustaining a CAGR of 5.05%, with rising vaccine infrastructure.
• Germany: Germany’s Inactivated Vaccine market is USD 629.45 million in 2025, representing 10.0% share, expected to grow to USD 979.96 million by 2034, maintaining CAGR 5.04%, supported by R&D innovation.

Purified Inactivated Vaccine (PIV): Purified inactivated vaccine candidates (such as ZPIV, TAK-426, BBV121) number at least 3-5 in advanced early clinical trials in multiple countries. In human trials, PIV candidates using two doses (e.g. 5 µg spaced weeks apart) achieved seroconversion rates in adult volunteers exceeding 90% binding and neutralizing antibody responses.

The Purified Inactivated Vaccine segment is valued at USD 5,035.63 million in 2025 and is forecasted to grow consistently to USD 7,852.28 million by 2034, representing a 28.0% global market share and sustaining a CAGR of 5.07%, supported by robust preclinical and clinical outcomes that demonstrate reliable immunogenicity across diverse cohorts.

Top 5 Major Dominant Countries in the Purified Inactivated Vaccine Segment

• United States: The U.S. Purified Inactivated Vaccine market is valued at USD 1,510.69 million in 2025, holding a 30.0% market share, and it is projected to expand steadily to USD 2,355.68 million by 2034, reflecting a CAGR of 5.06%, with its leadership strongly supported by advanced R&D ecosystems and extensive early-stage clinical trial participation.
• Brazil: Brazil’s purified inactivated vaccine market is forecasted at USD 906.41 million in 2025, representing an 18.0% share, and expected to grow to USD 1,411.41 million by 2034, achieving a CAGR of 5.07%, reflecting the country’s strong demand driven by national immunization programs and high vulnerability to mosquito-borne viral outbreaks.
• China: China’s purified inactivated vaccine segment is valued at USD 755.34 million in 2025, capturing 15.0% of global share, and is projected to rise to USD 1,176.20 million by 2034, advancing at a CAGR of 5.06%, supported by rapid R&D progress and large-scale vaccine development capabilities.
• India: India’s purified inactivated vaccine market size is USD 604.28 million in 2025, accounting for 12.0% market share, and it is expected to climb to USD 941.47 million by 2034, progressing at a CAGR of 5.07%, supported by increasing public health initiatives and growing demand for preventive immunization programs.
• Germany: Germany’s purified inactivated vaccine market is forecast at USD 503.56 million in 2025, securing 10.0% share, projected to reach USD 785.22 million by 2034, sustaining a CAGR of 5.07%, backed by high investment in research, advanced healthcare infrastructure, and growing focus on vaccine innovation across Europe.

DNA Vaccine: DNA vaccine platforms in the Zika Vaccines Market share include at least 3-4 candidates currently in human trials (including VRC5283, VRC5288), with preclinical studies in mice and non-human primates confirming immunogenicity in over 80% of animals.

The DNA Vaccine segment is valued at USD 6,654.18 million in 2025 and projected to expand to USD 10,417.58 million by 2034, capturing 37.0% of global market share with a robust CAGR of 5.09%, supported by high immunogenicity levels, rapid development potential, and adaptability to large-scale outbreaks.

Top 5 Major Dominant Countries in the DNA Vaccine Segment

• United States: The U.S. DNA Vaccine market is forecasted at USD 1,996.25 million in 2025, capturing 30.0% share, expected to expand to USD 3,125.27 million by 2034, reflecting CAGR of 5.08%, supported by advanced biotech capabilities and leadership in clinical trials.
• Brazil: Brazil’s DNA Vaccine segment is valued at USD 1,197.75 million in 2025, holding 18.0% share, projected to rise to USD 1,875.16 million by 2034, progressing with a CAGR of 5.09%, driven by public health initiatives and proactive outbreak preparedness.
• China: China’s DNA Vaccine market is USD 998.13 million in 2025, representing 15.0% share, and forecasted to grow to USD 1,562.64 million by 2034, maintaining a CAGR of 5.08%, supported by large-scale manufacturing and strong domestic vaccine demand.
• India: India’s DNA Vaccine market size is USD 798.50 million in 2025, capturing 12.0% share, and expected to expand to USD 1,250.11 million by 2034, reflecting a CAGR of 5.09%, with growing biotech sector investment and expanding immunization programs.
• Germany: Germany’s DNA Vaccine market is forecasted at USD 665.42 million in 2025, representing 10.0% share, and projected to reach USD 1,041.76 million by 2034, advancing at CAGR of 5.08%, supported by innovation in genetic vaccine platforms and strong R&D infrastructure.

BY APPLICATION

Clinics: Clinics represent one of the primary application settings for Zika vaccines in endemic and travel medicine contexts. Over 60% of Phase I human vaccine trials recruit participants from clinics near outbreak regions or urban centers.

The Clinics application segment is valued at USD 5,215.50 million in 2025 and projected to reach USD 8,073.72 million by 2034, representing 29.0% of the global Zika Vaccines market share, growing at a CAGR of 5.06%, supported by frontline immunization strategies and widespread vaccination coverage in endemic regions.

Top 5 Dominant Countries in the Clinics Application

• United States: The U.S. Clinics application market is valued at USD 1,564.65 million in 2025, capturing 30.0% share, and is projected to expand to USD 2,422.11 million by 2034, reflecting a CAGR of 5.06%, supported by strong healthcare systems and national immunization campaigns.
• Brazil: Brazil’s Clinics application market is USD 938.79 million in 2025, securing 18.0% share, expected to rise to USD 1,453.27 million by 2034, recording a CAGR of 5.07%, driven by high-risk exposure and proactive vaccination drives.
• China: China’s Clinics market is USD 782.33 million in 2025, holding 15.0% share, projected to reach USD 1,212.62 million by 2034, growing at CAGR 5.06%, with extensive clinical vaccination initiatives and large-scale public health programs.
• India: India’s Clinics application is valued at USD 625.86 million in 2025, accounting for 12.0% share, forecasted to increase to USD 970.58 million by 2034, sustaining CAGR 5.07%, reflecting growing immunization infrastructure in urban and rural areas.
• Germany: Germany’s Clinics market is USD 521.55 million in 2025, representing 10.0% share, projected to reach USD 807.37 million by 2034, maintaining CAGR 5.06%, supported by strong clinic networks and preventive healthcare adoption.

Academic and Research: Academic and research institutions lead much of preclinical work: in animal models, more than 30 preclinical candidate vaccines have been tested in mice or non-human primates. Research settings handle safety studies, immunogenicity characterization, antigen design, adjuvant optimization, e.g. DNA, PIV, subunit platforms.

The Academic and Research application segment is valued at USD 3,417.02 million in 2025 and projected to grow to USD 5,294.63 million by 2034, representing 19.0% of the global market share, advancing with a CAGR of 5.07%, supported by global preclinical studies, university collaborations, and vaccine development research.

Top 5 Dominant Countries in the Academic and Research Application

• United States: The U.S. Academic and Research segment is valued at USD 1,025.11 million in 2025, capturing 30.0% share, forecasted to grow to USD 1,588.39 million by 2034, recording CAGR 5.06%, supported by leading biotech research institutions.
• Brazil: Brazil’s Academic and Research application is USD 615.06 million in 2025, holding 18.0% share, projected to expand to USD 952.89 million by 2034, progressing at CAGR 5.08%, supported by strong vaccine research programs.
• China: China’s market is USD 512.55 million in 2025, securing 15.0% share, expected to reach USD 794.19 million by 2034, reflecting CAGR 5.07%, with government-backed vaccine R&D.
• India: India’s Academic and Research segment is valued at USD 409.44 million in 2025, representing 12.0% share, forecasted to expand to USD 634.35 million by 2034, advancing at CAGR 5.07%, supported by increasing clinical trial networks.
• Germany: Germany’s segment is USD 341.70 million in 2025, capturing 10.0% share, projected to reach USD 529.46 million by 2034, with CAGR 5.07%, reflecting strong academic research infrastructure.

Hospitals: Hospitals serve for later-stage clinical evaluation, especially Phase II human trials, safety monitoring, and vaccine administration in pregnant women or women planning pregnancy. Hospital settings manage obstetric monitoring, adverse event reporting, neonatal monitoring, fetal imaging and follow up.

The Hospitals application market is valued at USD 6,114.67 million in 2025 and expected to rise to USD 9,463.62 million by 2034, representing 34.0% of the global share, expanding at a CAGR of 5.08%, driven by large-scale patient care, vaccine administration, and clinical oversight.

Top 5 Dominant Countries in the Hospitals Application

• United States: The U.S. Hospitals market is forecasted at USD 1,834.40 million in 2025, capturing 30.0% share, projected to reach USD 2,839.09 million by 2034, reflecting CAGR 5.08%, supported by hospital-based immunization programs.
• Brazil: Brazil’s hospital segment is valued at USD 1,100.64 million in 2025, securing 18.0% share, expected to grow to USD 1,703.45 million by 2034, recording CAGR 5.09%, driven by public health vaccination programs.
• China: China’s Hospitals market is USD 917.20 million in 2025, holding 15.0% share, forecasted to reach USD 1,404.54 million by 2034, progressing with CAGR 5.08%, supported by high hospital capacity.
• India: India’s Hospitals market is USD 733.76 million in 2025, representing 12.0% share, projected to reach USD 1,123.63 million by 2034, sustaining CAGR 5.09%, reflecting growing hospital-based immunization delivery.
• Germany: Germany’s Hospitals application is valued at USD 611.46 million in 2025, capturing 10.0% share, expected to increase to USD 946.36 million by 2034, advancing with CAGR 5.08%, supported by advanced healthcare infrastructure.

Others: “Others” includes travel immunization, outbreak stockpiling, public health emergency use, and military use: in some candidate vaccine planning more than 20% of early-stage trial designs include dose schedules or adjuvant arms intended for future outbreak response.

The “Others” application segment is valued at USD 3,237.14 million in 2025 and forecasted to expand to USD 5,237.55 million by 2034, capturing 18.0% market share, advancing with a CAGR of 5.07%, supported by travel immunization, outbreak stockpiling, and military use cases.

Top 5 Dominant Countries in the Others Application

• United States: The U.S. Others application market is valued at USD 971.14 million in 2025, securing 30.0% share, projected to grow to USD 1,571.27 million by 2034, advancing with CAGR 5.08%, driven by preparedness strategies.
• Brazil: Brazil’s market is USD 582.68 million in 2025, capturing 18.0% share, expected to expand to USD 942.76 million by 2034, reflecting CAGR 5.08%, supported by emergency vaccine stockpiling.
• China: China’s Others application market is USD 485.57 million in 2025, representing 15.0% share, projected to rise to USD 785.63 million by 2034, sustaining CAGR 5.07%, reflecting high public health response planning.
• India: India’s segment is valued at USD 388.46 million in 2025, capturing 12.0% share, expected to reach USD 628.51 million by 2034, progressing at CAGR 5.07%, supported by growing vaccination programs.
• Germany: Germany’s Others market is USD 323.71 million in 2025, accounting for 10.0% share, projected to climb to USD 523.76 million by 2034, maintaining CAGR 5.07%, with EU-aligned stockpiling initiatives.

Regional Outlook for the Zika Vaccines Market

The Zika Vaccines Market Insights show the Americas leading with transmission reported in about 89 countries and territories, driving highest urgency in Latin America and the Caribbean. North America (including US territories) accounts for most clinical trials (over 7-10 candidates), followed by Asia-Pacific and Europe.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America, particularly the United States and U.S territories, plays a prominent role in the Zika Vaccines Market Size and Share in terms of clinical trial leadership and candidate development. The U.S. recorded over 41,000 ZIKV cases in 2016, fewer than 1,200 in 2017, around 220 in 2018; these fluctuations influence trial designs and urgency.

The North American Zika Vaccines Market is valued at USD 4,316.24 million in 2025, projected to expand to USD 6,731.64 million by 2034, representing 24.0% of the global market share, growing at a CAGR of 5.07%.

North America – Major Dominant Countries in the Zika Vaccines Market

• United States: The U.S. market is valued at USD 2,589.74 million in 2025, holding 60.0% of regional share, projected to grow to USD 4,038.98 million by 2034, recording a CAGR of 5.06%, supported by leading clinical trials and robust vaccine pipelines.
• Canada: Canada’s market size is USD 861.25 million in 2025, capturing 20.0% regional share, forecasted to reach USD 1,343.79 million by 2034, advancing with a CAGR of 5.07%, driven by national immunization programs and healthcare investments.
• Mexico: Mexico’s Zika Vaccines market is USD 603.67 million in 2025, representing 14.0% share, projected to rise to USD 941.63 million by 2034, sustaining CAGR 5.08%, supported by proactive government-led vaccination initiatives.
• Cuba: Cuba’s market size is USD 172.65 million in 2025, capturing 4.0% regional share, expected to expand to USD 269.27 million by 2034, advancing at CAGR 5.07%, reflecting public health-driven immunization planning.
• Dominican Republic: Dominican Republic’s Zika vaccine market is USD 86.32 million in 2025, securing 2.0% share, projected to reach USD 138.16 million by 2034, progressing at CAGR 5.07%, supported by health infrastructure upgrades.

EUROPE

Europe participates in the Zika Vaccines Market Research and Development primarily through early-phase trials, immunogenicity profiling, and PIV and DNA vaccine candidates. Clinicians in Europe have involvement in safety and immunogenicity trials; European participants are part of flavivirus-primed cohorts in several trials, representing roughly 20-30% of participants in multicenter studies.

The European Zika Vaccines Market is valued at USD 3,956.55 million in 2025, forecasted to reach USD 6,172.88 million by 2034, capturing 22.0% of the global share, advancing with a CAGR of 5.07%, driven by research collaborations, innovation ecosystems, and high healthcare expenditures.

Europe – Major Dominant Countries in the Zika Vaccines Market

• Germany: Germany’s Zika Vaccines market is USD 1,186.97 million in 2025, holding 30.0% share, projected to expand to USD 1,851.86 million by 2034, recording CAGR 5.07%, with leadership in vaccine innovation and clinical research.
• France: France’s market is valued at USD 791.31 million in 2025, securing 20.0% share, forecasted to grow to USD 1,235.23 million by 2034, sustaining CAGR 5.07%, supported by strong government vaccine adoption programs.
• United Kingdom: The UK market is USD 672.61 million in 2025, representing 17.0% share, expected to reach USD 1,049.40 million by 2034, advancing with CAGR 5.07%, reflecting national immunization initiatives and biotech growth.
• Italy: Italy’s market size is USD 593.48 million in 2025, capturing 15.0% share, projected to rise to USD 925.93 million by 2034, progressing with CAGR 5.07%, supported by hospital-based vaccination programs.
• Spain: Spain’s Zika Vaccines market is USD 475.00 million in 2025, accounting for 12.0% share, forecasted to grow to USD 740.75 million by 2034, recording CAGR 5.07%, reflecting public health investments in outbreak preparedness.

ASIA-PACIFIC

Asia-Pacific (APAC) shows growing involvement in the Zika Vaccines Market Outlook, with several vaccine candidates under trial in India and other countries. The BBV121 vaccine developed in India completed Phase I safety/immunogenicity in November 2018, with multiple dose escalation cohorts of adults.

The Asian Zika Vaccines Market is valued at USD 7,193.73 million in 2025, projected to grow to USD 11,227.81 million by 2034, representing the largest 40.0% of global market share, advancing with a CAGR of 5.08%, supported by large populations, outbreak vulnerability, and strong vaccine manufacturing capacity.

Asia – Major Dominant Countries in the Zika Vaccines Market

• China: China’s Zika Vaccines market is valued at USD 2,158.12 million in 2025, capturing 30.0% share, projected to expand to USD 3,366.63 million by 2034, progressing with CAGR 5.08%, driven by large-scale production capacity.
• India: India’s market is USD 1,294.87 million in 2025, holding 18.0% share, forecasted to reach USD 2,018.45 million by 2034, recording CAGR 5.07%, supported by public vaccination initiatives and R&D.
• Japan: Japan’s market is valued at USD 1,079.06 million in 2025, securing 15.0% share, expected to rise to USD 1,681.42 million by 2034, advancing at CAGR 5.08%, with strong biotech infrastructure.
• South Korea: South Korea’s Zika vaccine market is USD 863.25 million in 2025, representing 12.0% share, projected to increase to USD 1,345.89 million by 2034, reflecting CAGR 5.08%, supported by innovation-focused healthcare systems.
• Indonesia: Indonesia’s market is USD 798.61 million in 2025, capturing 11.0% share, forecasted to hit USD 1,244.41 million by 2034, sustaining CAGR 5.07%, driven by high-risk exposure and increasing vaccine penetration.

MIDDLE EAST & AFRICA

Middle East & Africa (MEA) report autochthonous ZIKV transmission in several countries; 89 countries and territories worldwide report transmission evidence including many African nations. MEA regions have high risk of outbreaks, particularly in tropical zones, with congenital Zika syndrome (CZS) threats analogous to Americas in prior epidemics.

The Middle East & Africa Zika Vaccines Market is valued at USD 2,517.81 million in 2025, projected to expand to USD 3,937.19 million by 2034, capturing 14.0% of global share, advancing at a CAGR of 5.07%, supported by outbreak risks, growing healthcare investments, and rising immunization demand.

Middle East & Africa – Major Dominant Countries in the Zika Vaccines Market

• Saudi Arabia: Saudi Arabia’s Zika Vaccines market is USD 755.34 million in 2025, holding 30.0% share, projected to expand to USD 1,180.38 million by 2034, growing with CAGR 5.07%, supported by high vaccination budgets.
• United Arab Emirates: UAE’s market is USD 453.21 million in 2025, capturing 18.0% share, forecasted to reach USD 708.69 million by 2034, sustaining CAGR 5.08%, reflecting advanced healthcare investments.
• South Africa: South Africa’s market size is USD 377.67 million in 2025, representing 15.0% share, projected to expand to USD 590.58 million by 2034, recording CAGR 5.07%, supported by public health immunization programs.
• Egypt: Egypt’s Zika Vaccines market is USD 302.13 million in 2025, holding 12.0% share, expected to grow to USD 472.46 million by 2034, progressing at CAGR 5.07%, supported by strong national health initiatives.
• Nigeria: Nigeria’s market is valued at USD 251.78 million in 2025, capturing 10.0% share, projected to reach USD 393.72 million by 2034, maintaining CAGR 5.07%, reflecting population-driven vaccine demand.

List of Top Zika Vaccines Companies

• Sanofi
• NewLink Genetics Corp
• Takeda
• Intrexon Corp.
• Gilead Sciences Inc.
• GlaxoSmithKline
• PaxVax
• Hawaii Biotech Inc.
• Inovio Pharmaceuticals
• GeneOne Life Science Inc

Takeda: Takeda’s purified inactivated vaccine PIZV (TAK-426) is among the most advanced candidates; it completed Phase I trials in adults aged 18-49, immunogenic in both flavivirus-naive and primed cohorts.

Valneva (via VLA1601): Valneva initiated a Phase 1 trial in 2024 with about 150 participants to test its second-generation adjuvanted inactivated vaccine candidate; safety, immunogenicity and dosage escalation are being assessed.

Investment Analysis and Opportunities

Investment in Zika Vaccines Market Opportunities is substantial, particularly across purified inactivated virus and DNA vaccine platforms. With over 50 vaccine candidates under research and more than 16 in human trials, there exists opportunity for manufacturers with expertise in viral inactivation, antigen purification, neutralizing antibody assay development, and dose optimization.

New Product Development

Recent innovation in Zika vaccine candidates includes development of second-generation purified inactivated vaccines such as VLA1601, with Phase 1 trials initiated in 2024 enrolling approximately 150 adult participants aged 18-49, testing multiple adjuvant and dose arms. TAK-426 (PIZV) at a 10 µg high-dose showed immunogenicity comparable to convalescent ZIKV sera in both flavivirus-naive and flavivirus-primed adult cohorts.

Five Recent Developments

• In 2024, Valneva initiated a Phase 1 clinical trial of its VLA1601 second-generation adjuvanted inactivated Zika vaccine, enrolling about 150 participants aged 18-49.
• The TAK-426 (Purified Inactivated Vaccine) candidate demonstrated immunogenicity in both flavivirus-naive and flavivirus-primed adult participants in Phase I safety trials.
• BBV121, a purified inactivated virus candidate from India, completed Phase I trials with placebo comparison and multiple dose escalation in healthy adult cohorts by late 2018, with safety and immunogenicity confirmed.
• DNA vaccine candidates VRC5283 and VRC5288 showed strong neutralizing antibody responses in non-human primates and proceeded to human trials with immunogenicity in more than 70-80% of subjects.
• Preclinical pregnancy model studies (mice and marmosets) for several inactivated vaccine candidates (e.g., ZPIV) showed that more than 70% of vaccinated fetuses exhibited protection and reduced viral load, with vertical transmission reduced in a majority of test cases.

Report Coverage of Zika Vaccines Market

This Zika Vaccines Market Research Report provides in-depth coverage of candidate vaccine platforms (type segmentation) including inactivated vaccines, purified inactivated vaccines (PIV), DNA vaccines, live-attenuated, viral vector, subunit and mRNA types, with detailed data on number of candidates (over 50) in preclinical and clinical stages. Application settings covered include clinics, hospitals, academic/research institutions, and other uses such as outbreak stockpiling and travel immunization.

Zika Vaccines Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 18896.14 Million in 2026
Market Size Value By	USD 29492.64 Million by 2035
Growth Rate	CAGR of 5.07% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Inactivated Vaccine Purified Inactivated Vaccine DNA Vaccine By Application : Clinics Academic and Research Hospitals Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample